

Role of human AADAC on hydrolysis of eslicarbazepine acetate and effects of *AADAC* genetic polymorphisms on hydrolase activity

Keiya Hirosawa, Tatsuki Fukami, Kiyomichi Tashiro, Yoshiyuki Sakai, Fumiya Kisui,
Masataka Nakano, Miki Nakajima

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University,
Kakuma-machi, Kanazawa 920-1192, Japan (K. H., T. F., K. T., Y. S., Ma.N., Mi. N.); WPI
Nano Life Science Institute, Kakuma-machi, Kanazawa 920-1192, Japan (T. F., Ma. N., Mi.
N.)

Running title: Role of AADAC on eslicarbazepine acetate hydrolysis

To whom all correspondence should be sent:

Tatsuki Fukami

Drug Metabolism and Toxicology

Faculty of Pharmaceutical Sciences

Kanazawa University

Kakuma-machi, Kanazawa 920-1192, Japan

Tel: +81-76-234-4438/Fax: +81-76-264-6282

E-mail: tatsuki@p.kanazawa-u.ac.jp

Number of text pages: 26

Number of tables: 5

Number of figures: 6

Number of references: 39

Number of words in abstract: 248 words

Number of words in introduction: 558 words

Number of words in discussion: 1018 words

ABBREVIATIONS: AADAC, arylacetamide deacetylase; BNPP, bis (*p*-nitrophenyl) phosphate; CES, carboxylesterase; DFP, diisopropyl fluorophosphate; EGCg, epigallocatechin gallate; HIC, human intestinal cytosol; HIM, human intestinal microsomes; HLC, human liver cytosol; HLM, human liver microsomes; HPLC, high-performance liquid chromatography; PMSF, phenylmethylsulfonyl fluoride; PNPA, *p*-nitrophenyl acetate; PON, paraoxonase; SNP, single nucleotide polymorphism

Abstract

Human arylacetamide deacetylase (AADAC) plays a role in the detoxification or activation of drugs and is sometimes involved in the incidence of toxicity by catalyzing hydrolysis reactions. AADAC prefers compounds with relatively small acyl groups, such as acetyl groups. Eslicarbazepine acetate, an antiepileptic drug, is a prodrug rapidly hydrolyzed to eslicarbazepine. We sought to clarify whether AADAC might be responsible for the hydrolysis of eslicarbazepine acetate. Eslicarbazepine acetate was efficiently hydrolyzed by human intestinal and liver microsomes and recombinant human AADAC. The hydrolase activities in human intestinal and liver microsomes were inhibited by epigallocatechin gallate, a specific inhibitor of AADAC, by 82% and 88% of the control, respectively. The hydrolase activities in liver microsomes from 25 human livers were significantly correlated ($r = 0.87$, $P < 0.001$) with AADAC protein levels, suggesting that the enzyme AADAC is responsible for the hydrolysis of eslicarbazepine acetate. The effects of genetic polymorphisms of AADAC on eslicarbazepine acetate hydrolysis were examined by using the constructed recombinant AADAC variants with T74A, V172I, R248S, V281I, N366K, or X400Q. AADAC variants with R248S or X400Q showed lower activity than wild type (5% or 21%, respectively), whereas those with V172I showed higher activity than wild type (174%). Similar tendencies were observed in the other 4 substrates of AADAC; that is, *p*-nitrophenyl acetate, ketoconazole, phenacetin, and rifampicin. Collectively, we found that eslicarbazepine acetate is specifically and efficiently hydrolyzed by human AADAC, and several AADAC polymorphic alleles would be a factor affecting the enzyme activity and drug response.

Significance Statement

This is the first study to clarify that AADAC is responsible for the activation of eslicarbazepine acetate, an antiepileptic prodrug, to eslicarbazepine, an active form, in the human liver and intestines. In addition, we found that several *AADAC* polymorphic alleles would be a factor affecting the enzyme activity and drug response.

Introduction

Drug-metabolizing enzymes play roles in the detoxification or activation of drugs and sometimes cause drug-induced toxicity by forming reactive metabolites. Among drug-metabolizing enzymes, cytochrome P450 (P450) is responsible for the metabolism of over 50% of clinical drugs with the highest contribution. Recently, a better understanding of roles of enzymes other than P450, non-P450 enzymes, is required, because their contribution for the metabolism of clinical drugs has gradually increased (Cerny, 2016). Hydrolases catalyze the hydrolysis of ester, amide, and thioester bonds and are largely involved in the activation of prodrugs, detoxification, and sometimes toxicity (Cerny, 2016; Fukami and Yokoi, 2012). Among hydrolases, carboxylesterase (CES) is the best-characterized hydrolase family, and two isoforms, CES1 and CES2, mainly catalyze the hydrolysis reaction of drugs (Fukami and Yokoi, 2012). CES1 is predominantly expressed in the liver, whereas CES2 is expressed in the small intestine as well as liver. In addition to CES, our laboratory has demonstrated that arylacetamide deacetylase (AADAC) participates in the hydrolysis of clinical drugs including aromatic amides/esters such as flutamide (Watanabe et al., 2009), phenacetin (Watanabe et al., 2010), and prasugrel (Kurokawa et al., 2016), and aliphatic amides/esters such as rifamycins (rifampicin, rifabutin, and rifapentine) (Nakajima et al., 2011), and ketoconazole (Fukami et al., 2016). AADAC is mainly expressed in the human liver and intestines (Watanabe et al., 2009). We have reported that human hydrolase(s) involved in the hydrolysis of the target compounds can be roughly predicted based on the size of the acyl or alcohol/amine group in the compounds (Fukami et al., 2015). CES1 prefers compounds with relatively large acyl groups, whereas CES2 and AADAC prefer compounds with relatively small acyl groups. Especially, AADAC prefers compounds with acetyl group.

Carbamazepine, a widely used antiepileptic drug that was developed in the 1960s, sometimes causes adverse reactions, including central nervous system disorders. It has been suggested that an intermediate metabolite, carbamazepine 10,11-epoxide (Fig. 1), could be the cause of the adverse reactions of carbamazepine (Fricke-Galindo et al., 2018). To reduce

carbamazepine-induced adverse reactions, oxcarbazepine was developed (Koch and Polman, 2009). Oxcarbazepine is a prodrug that is converted to eslicarbazepine (*S*-licarbazepine) and *R*-licarbazepine via a reduction reaction in the human liver, but only the former metabolite has pharmacological actions (Malátková et al., 2014; Potschka H et al., 2014). Later, eslicarbazepine acetate was developed with the aim of efficient and specific formation of eslicarbazepine (Nunes et al., 2013) (Fig. 1). Eslicarbazepine acetate, of which at least 90% of the dose is absorbed from the intestines regardless of food intake, is quickly hydrolyzed to eslicarbazepine by first-pass metabolism (Maia et al., 2012; Almeida et al., 2008). According to the known substrate preference of drug-metabolizing hydrolases (Fukami et al., 2015), it is conceivable that eslicarbazepine acetate might be hydrolyzed by AADAC because it has an acetic acid ester.

In this study, we sought to identify the enzyme(s) responsible for the hydrolysis of eslicarbazepine acetate. For the *AADAC* gene, many SNPs (single nucleotide polymorphisms) are registered on dbSNP (<https://www.ncbi.nlm.nih.gov/snp/>). However, the significance of most SNPs, except g.14008T>C (X400Q), which has been found to substantially decrease enzyme activity (Shimizu et al., 2012), remains to be determined. If AADAC is the enzyme responsible for eslicarbazepine acetate hydrolysis, it is possible that SNPs in the *AADAC* gene affect the drug response. We examined the effects of six kinds of SNPs causing amino acid substitutions on eslicarbazepine acetate hydrolysis.

Materials and Methods

Chemicals and Reagents. Eslicarbazepine acetate and eslicarbazepine were purchased from Tokyo Chemical Industry (Tokyo, Japan) and Tocris Bioscience (Bristol, UK), respectively. Epigallocatechin gallate (EGCg), diisopropyl fluorophosphate (DFP), flutamide, *p*-nitrophenol, 4-nitro-3-(trifluoromethyl)phenylamine, phenacetin, phenylmethylsulfonyl fluoride (PMSF), rifampicin, and vinblastine were purchased from FUJIFILM Wako Pure (Osaka, Japan). Bis (*p*-nitrophenyl) phosphate (BNPP), *p*-nitrophenyl acetate (PNPA), and *p*-phenetidine were purchased from Sigma-Aldrich (St. Louis, MO). Ketoconazole, *N*-deacetyl ketoconazole, and telmisartan were purchased from LKT Laboratories (St. Paul, MN). 25-Deacetyl rifampicin was purchased from Toronto Research Chemicals (Toronto, Canada). Human intestinal and liver microsomes (pooled HIM, *n* = 7 and pooled HLM, *n* = 50) and human liver cytosol (pooled HLC, *n* = 50) were purchased from Corning (Corning, NY). Human intestinal cytosol (pooled HIC, *n* = 6) was purchased from XenoTech (Lenexa, KS). A Bac-to-Bac Baculovirus Expression System, Sf-900 II SFM insect cell medium, and *Spodoptera frugiperda* Sf21 cells were purchased from Thermo Fisher Scientific (Waltham, MA). *Taq* DNA polymerase was purchased from Greiner (Tokyo, Japan). The pTarget Mammalian Expression Vector was purchased from Promega (Madison, WI). Recombinant human AADAC, CES1, and CES2 expressed in baculovirus-infected insect cells were prepared previously (Fukami et al., 2010; Watanabe et al., 2010). All other reagents used in this study were of analytical or the highest quality grade commercially available.

Preparation of Microsomal Fractions from A Panel of 25 Individual Human Livers.

Human liver samples from 25 individual donors were obtained from the National Disease Research Interchange (Philadelphia, PA) through the Human and Animal Bridging Research Organization (Chiba, Japan). HLM were prepared according to a previously reported method (Kobayashi et al., 2012). The use of liver samples was approved by the Ethics Committee of Kanazawa University (Kanazawa, Japan). The donor information is shown in Table 1.

Eslicarbazepine Acetate Hydrolase Activity. Eslicarbazepine acetate hydrolase activity was determined as follows: a typical incubation mixture (final volume, 0.2 mL) contained 100 mM Tris-HCl buffer (pH 7.4) and enzyme sources (pooled HIM, HIC, HLM, HLC, and homogenates of Sf21 cells expressing human AADAC, CES1, or CES2: 0.1 mg/mL). After a 2-min preincubation at 37°C, eslicarbazepine acetate dissolved in DMSO was added to the incubation mixture so that the final concentration of DMSO was 1.0%. The concentration of eslicarbazepine acetate was set to 1 mM. After a 5-min incubation at 37°C, the reaction was terminated by the addition of 100 μ L of ice-cold methanol. In preliminary experiments, we confirmed that the linearities of eslicarbazepine formation in terms of the protein concentration and incubation time were up to 0.2 mg/mL and 10 min, respectively. After the removal of the protein by centrifugation at 20,380g for 5 min, a 60 μ L aliquot of the supernatant was subjected to HPLC. The HPLC equipment consisted of an L-2100 pump (Hitachi, Tokyo, Japan), an L-2200 autosampler (Hitachi), an L-2400 UV detector (Hitachi), and a D-2500 HPLC Chromato-Integrator (Hitachi) equipped with Wakopak eco-ODS (4.6 \times 150 mm ID, 5 μ m, Wako, Tokyo, Japan). The eluent was monitored at 235 nm. The mobile phase was 35% methanol, and the flow rate was 1.0 mL/min. The column temperature was 35°C. The quantification of the metabolites was performed by comparing the HPLC peak heights to those of an authentic standard.

Kinetic Analysis. Kinetic analysis was performed using pooled HIM, HLM, and recombinant AADAC with substrate concentrations ranging from 0.1 to 5 mM. The kinetic parameters were estimated from a curve fitted using a computer program designed for nonlinear regression analysis (KaleidaGraph; Synergy Software, Reading, PA).

Inhibition Analysis of Eslicarbazepine Acetate Hydrolase Activity. To examine the responsibility of AADAC for eslicarbazepine acetate hydrolysis in humans, inhibition analyses were performed using pooled HIM, HLM, and recombinant AADAC. DFP and

BNPP are serine hydrolase inhibitors (Heymann and Krisch, 1967; Yamaori et al., 2006). PMSF is an inhibitor for both CES enzymes, telmisartan is a specific inhibitor for CES2, and vinblastine is an inhibitor for CES2 and AADAC (Shimizu et al., 2014). EGCg is a specific inhibitor for AADAC (Yasuda et al., in preparation). CaCl_2 is an activator of paraoxonase (PON). The concentrations of the inhibitors were set according to those previous reports as follows: 100 μM for DFP, BNPP, and PMSF; 5 μM for telmisartan; 50 μM for vinblastine and EGCg; and 1 mM for CaCl_2 . DFP, PMSF, telmisartan, and vinblastine were dissolved in DMSO such that the final concentration of DMSO in the incubation mixture was 2%. The other inhibitors were dissolved in distilled water. The experimental procedure and conditions were the same as above.

Immunoblot Analysis. SDS-polyacrylamide gel electrophoresis and immunoblot analysis for human AADAC were performed according to our previous report (Watanabe et al., 2009). Human liver microsomes (30 μg) were separated on 10% polyacrylamide gels and electrotransferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore Corporation, Billerica, MA). The membrane was probed with monoclonal mouse anti-human AADAC antibody (Abnova, Taipei City, Taiwan) and the corresponding fluorescent dye-conjugated secondary antibody. The band densities were quantified with an Odyssey Infrared Imaging system (LI-COR Biosciences, Lincoln, NE). This analysis was performed in the linear range of band intensity with respect to the amount of protein.

Construction of Expression Plasmids for AADAC Variants. The expression plasmids for 4 kinds of AADAC variants causing amino acid substitutions, c.310A>G (T74A), c.604G>A (V172I), c.834A>T (R248S), or c.1188C>G (N366K), were constructed according to our previous reports (Watanabe et al., 2009; Shimizu et al., 2012). The plasmids for wild-type and V281I or Q400X variants were previously constructed (Shimizu et al., 2012). These six SNPs were focused based on the over 0.1% minor-allele frequencies in the dbSNP database (Table 2). Each mutation was introduced into the pTarget mammalian expression vector of AADAC

wild-type through site-directed mutagenesis with a Quick Change II XL site-directed mutagenesis kit with the primer sets (Table 3). Nucleotide sequences were confirmed with DNA sequence analysis. The AADAC cDNA in the pTargetT vector was then transferred into the pFastBac1 vector using appropriate restriction enzymes.

Expression of Human AADAC Variants in Sf21 Cells. The pFastBac1 vectors containing each AADAC cDNA were transformed into DH10Bac competent cells, followed by transposition of the inserts into bacmid DNA. A Bac-to-Bac Baculovirus Expression System was used to express human AADAC, as described in our previous report (Watanabe et al., 2010). The AADAC protein levels of the constructed expression systems were determined by immunoblotting.

Hydrolase Activities for PNPA, Ketoconazole, Phenacetin, and Rifampicin by AADAC Variants. PNPA, ketoconazole, phenacetin, and rifampicin hydrolase activities were determined according to our previous reports (Shimizu et al., 2012; Fukami et al., 2016; Watanabe et al., 2010; Nakajima et al., 2011) with slight modifications. The concentrations of homogenates of Sf21 cells expressing AADAC wild-type or variants were set as follows: PNPA hydrolase activity, 0.05 mg/mL; ketoconazole hydrolase activity, 1.0 mg/mL; phenacetin hydrolase activity, 0.4 mg/mL; and rifampicin hydrolase activity, 0.4 mg/mL. The concentrations of PNPA, ketoconazole, phenacetin, and rifampicin were set at 100 μ M, 20 μ M, 3 mM, and 200 μ M, respectively.

Genomic DNA. Genomic DNA samples were extracted from human blood samples by using a Puregene DNA isolation kit (Gentra Systems, Inc., Minneapolis, MN). The blood samples were from 176 Japanese, 205 Korean, 209 Caucasian, and 218 African-American healthy subjects who provided written informed consent. The use of genomic DNA samples was approved by the Ethics Committee of Kanazawa University (Kanazawa, Japan),

Soonchunhyang University Hospital (Chonan, Korea), and the Human Studies Committee of Washington University School of Medicine (St. Louis, MO).

Genotyping of AADAC Alleles. The frequencies of AADAC variant alleles having g.10583G>A (V172I) or g.13452A>T (R248S) were determined using genomic DNA samples. In addition to these 2 SNPs, the frequency of a whole gene deletion type, which has been suggested to be associated with Tourette syndrome in Europeans (Bertelsen et al., 2016), was determined. For genotyping of the alleles having g.10583G>A (V172I) or g.13452A>T (R248S), polymerase chain reaction (PCR)-restriction fragment length polymorphism analyses were performed. The PCR mixture contained genomic DNA (100 ng), 1 × PCR buffer [67 mM Tris-HCl, pH 8.8, 16.6 mM (NH₄)₂SO₄, 0.45% Triton X-100, 0.02% gelatin], 1.5 mM MgCl₂, 0.2 mM dNTPs, 0.4 μM each primer (Table 3), and 0.5 U of *Taq* polymerase in a final volume of 25 μL. After an initial denaturation at 94°C for 3 min, the amplification was performed with denaturation at 94°C for 25 s, annealing at 54°C for 25 s, and extension at 72°C for 50 s for 30 cycles, followed by a final extension at 72°C for 5 min. The PCR products were digested with *EcoR* I and *Hinf* I for g.10583G>A and g.13452A>T, respectively. The restriction products underwent electrophoresis in a 3% agarose gel. In the genotyping of g.10583G>A, the wild-type yielded a 125-base pair fragment, and the variant yielded 101- and 24-base pair fragments. In the genotyping of g.13452A>T, the wild-type yielded 145- and 72-base pair fragments, and the variant yielded a 217-base pair fragment. For genotyping of the AADAC whole gene deletion type, allele-specific PCR was performed. The locations of the primer pairs used for genotyping of the gene deletion type are shown in Supplementary Fig. 1S. The PCR conditions were the same as above. The 584- and 679-base pair fragments should be detected for the wild type and deletion type, respectively.

Statistical Analysis. Statistical significance between two groups was determined by an unpaired, two-tailed Student's *t*-test, and statistical significance between multiple groups was determined by ANOVA followed by Tukey's test using Instat 2 software (GraphPad Software,

San Diego, CA). Correlation analysis was performed using the Spearman rank method. A value of $P < 0.05$ was considered statistically significant.

Results

Eslicarbazepine Acetate Hydrolase Activities by Various Enzyme Sources. It is known that eslicarbazepine acetate is prominently hydrolyzed to eslicarbazepine by first-pass metabolism (Almeida et al., 2008). In this study, eslicarbazepine acetate hydrolase activities in pooled HIM, HIC, HLM, and HLC were evaluated at a substrate concentration of 1 mM, assuming the concentration in the intestinal lumen, although it was not expected to reach in the liver at this concentration (Fig. 2). The eslicarbazepine acetate hydrolase activities in HIM and HLM were 114.2 ± 4.2 nmol/min/mg protein and 189.6 ± 13.4 nmol/min/mg protein, respectively, whereas HIC and HLC showed marginal activity, suggesting that eslicarbazepine acetate is efficiently hydrolyzed in both the intestines and liver, and the responsible enzyme(s) is localized in the endoplasmic reticulum. Then, to examine the involvement of major drug-metabolizing hydrolases, CES1, CES2, or AADAC in eslicarbazepine acetate hydrolysis, the activities were measured by using their recombinant enzymes. As shown in Fig. 2, AADAC showed prominent eslicarbazepine acetate hydrolase activity (92.7 ± 4.2 nmol/min/mg protein), whereas CES1 (1.7 ± 0.2 nmol/min/mg protein) and CES2 (0.4 ± 0.3 nmol/min/mg protein) showed marginal activities, which were close to the activity of the control (0.3 ± 0.2 nmol/min/mg protein). Since AADAC is localized on the endoplasmic reticulum membrane in the intestine and liver, whereas CES1 (liver) and CES2 (intestine and liver) are localized in the cytosol as well as the endoplasmic reticulum (Frick et al., 2004; Tabata et al., 2004; Xu et al., 2002), it was suggested that the eslicarbazepine acetate hydrolase activities in HIM and HLM may be explained by AADAC.

Kinetic Analysis of Eslicarbazepine Acetate Hydrolase Activities in HIM, HLM, and Recombinant AADAC. Kinetic analysis for eslicarbazepine acetate hydrolysis was performed using pooled HIM, HLM, and recombinant AADAC (Fig. 3). The kinetics in all cases were fitted to Michaelis-Menten kinetics, and the Eadie-Hofstee plots showed straight lines. The K_m , V_{max} , and CL_{int} values in HIM were 1.16 ± 0.20 mM, 202.3 ± 7.2

nmol/min/mg protein, and 0.17 ± 0.02 mL/min/mg protein, respectively, and those in HLM were 0.72 ± 0.08 mM, 283.7 ± 4.1 nmol/min/mg protein, and 0.40 ± 0.05 mL/min/mg protein, respectively (Table 4). Those by recombinant AADAC were 0.79 ± 0.11 mM, 157.5 ± 3.9 nmol/min/mg protein, and 0.20 ± 0.02 mL/min/mg protein, respectively (Table 4). The K_m value by HIM was slightly higher than that by recombinant AADAC, but the K_m value by HLM was close to that by recombinant AADAC. Thus, it was suggested that an enzyme catalyzing eslicarbazepine acetate hydrolysis in HIM and HLM would be AADAC.

Inhibition Analysis of Eslicarbazepine Acetate Hydrolase Activities in HIM, HLM, and Recombinant AADAC. To examine whether AADAC is a principal enzyme for eslicarbazepine acetate hydrolysis in human intestines and liver, inhibition analysis using representative inhibitors for eslicarbazepine acetate hydrolase activities in HIM, HLM, and recombinant AADAC was performed (Fig. 4). The eslicarbazepine acetate hydrolase activities in HIM and HLM were inhibited by DFP and BNPP, serine hydrolase inhibitors, but not by PMSF, a CES inhibitor, and telmisartan, a specific CES2 inhibitor. The activities were potently inhibited by vinblastine, an inhibitor of AADAC and CES2, and EGCg, a specific inhibitor of AADAC. The potent inhibition of AADAC by vinblastine and EGCg was confirmed by using recombinant AADAC. CaCl_2 , a PON activator, did not alter the activities. These results strengthened the finding that AADAC is responsible for eslicarbazepine acetate hydrolysis in the human intestine and liver.

Correlation Analysis between Eslicarbazepine Acetate Hydrolase Activities and AADAC Protein Levels in A Panel of 25 Human Liver Microsomes. To further examine the responsibility of AADAC for eslicarbazepine acetate hydrolysis, correlation analysis between eslicarbazepine acetate hydrolase activities and AADAC protein levels was performed using a panel of liver microsomes from 25 individuals (Fig. 5). The eslicarbazepine acetate hydrolase activities ranged from 20.1 to 190.4 nmol/min/mg protein, resulting in 9.5-fold interindividual variability. The AADAC protein levels ranged from 1.0 to 4.0, resulting in 4-fold

interindividual variability. As shown in Fig. 5, the eslicarbazepine acetate hydrolase activities were significantly correlated with AADAC protein levels ($r = 0.87$, $P < 0.001$), supporting that AADAC is a principal enzyme for eslicarbazepine acetate hydrolysis.

Effects of Genetic Polymorphisms of AADAC on Hydrolase Activities for

Eslicarbazepine Acetate and Other AADAC Substrates. To examine the effects of genetic polymorphisms of AADAC on eslicarbazepine acetate hydrolase activities, recombinant AADAC variants with T74A, V172I, R248S, and N366K were constructed. In addition, recombinant AADAC variants with V281I and X400Q, which had been constructed in our previous study (Shimizu et al., 2012), were also used (Fig. 6A). By immunoblotting, the expression levels of recombinant AADAC variants with T74A, V172I, R248S, V281I, N366K, and X400Q relative to that of wild type were calculated to be 6.71, 1.55, 2.25, 3.27, 2.87, and 5.54, respectively (data not shown). These values were used to normalize the hydrolase activities by recombinant AADAC variants. The eslicarbazepine acetate hydrolase activity by AADAC wild type was 101.1 ± 3.4 nmol/min/mg protein. As shown in Fig. 6A, the eslicarbazepine acetate hydrolase activity by T74A, V281I or N366K variant was slightly but significantly higher than that by wild type (% of normalized activity by wild type: $106.4 \pm 1.8\%$, $125.1 \pm 6.4\%$ or $121.7 \pm 5.0\%$, respectively). The activity of the V172I variant was significantly higher than that of the wild type ($173.9 \pm 8.9\%$), whereas the activities of the R248S or X400Q variant were significantly lower than that of the wild type ($5.4 \pm 0.7\%$ or $21.1 \pm 1.2\%$, respectively).

To investigate whether similar trends were observed in the hydrolysis of other AADAC substrates, PNPA, ketoconazole, phenacetin, and rifampicin hydrolase activities were measured. As shown in Figs. 6B-E, the T74A, V281I, and N366K variants had activities similar to those in wild types. The V172I variant commonly had higher activities, whereas the R248S and X400Q variants had lower activities than wild type. The trend was consistent with that observed in eslicarbazepine acetate hydrolysis. Thus, we found that the V172I variant has

significantly increased activity, whereas R248S and X400Q variants have significantly decreased activities regardless of the substrates.

Allele Frequencies of V172I or R248S Variant as well as A Whole Gene Deletion Type in 176 Japanese, 205 Koreans, 209 Caucasians, and 218 African-Americans. Previously, we reported that the allele frequencies of the X400Q variant in Caucasians and African Americans were 1.3% and 2.0%, respectively, whereas the variant was not found in Japanese and Koreans (Shimizu et al., 2012). In this study, the allele frequencies of g.10583G>A (V172I), g.13452A>T (R248S), and a whole gene deletion type found in Europeans (Bertelsen et al., 2016) were determined in the above 4 populations (Table 5). For the SNP g.10583G>A (V172I), 2 heterozygotes were found in 218 African Americans, resulting in a frequency of 0.5%, but no carriers were detected in the other populations. For the SNP g.13452A>T (R248S), no carriers were found in this study. For the whole gene deletion type, 3 heterozygotes were found in 209 Caucasians, resulting in a frequency of 0.7%, but no carriers were found in the other populations. Since the allele frequencies of these variants appear to be quite low, further investigation with an increased number of samples would be required to determine more accurate allele frequencies and their ethnic differences.

Discussion

Eslicarbazepine acetate is a prodrug that has been developed to be efficiently converted to an active form and to lower toxicity by chemical modifications of carbamazepine and oxcarbazepine (Nunes et al., 2013; Galiana et al., 2017). Because eslicarbazepine acetate is an acetylated form of eslicarbazepine, it was surmised to be hydrolyzed by AADAC according to its substrate preference. In this study, we sought to examine whether AADAC is an enzyme responsible for the hydrolysis of eslicarbazepine acetate in humans.

Clinical studies have shown that eslicarbazepine, but not eslicarbazepine acetate, was detected in the blood after oral administration of eslicarbazepine acetate (Almeida et al., 2008), implying that eslicarbazepine acetate is rapidly and completely hydrolyzed in the body. Therefore, we measured eslicarbazepine acetate hydrolase activities in HIM, HIC, HLM, and HLC and found that eslicarbazepine acetate was efficiently hydrolyzed by HIM and HLM (Fig. 2). Then, it was demonstrated that eslicarbazepine acetate was hydrolyzed by recombinant AADAC but not CES1 or CES2 (Fig. 2). Unlike CES1 and CES2, which are localized both in the endoplasmic reticulum and cytosol (Satoh and Hosokawa, 2006; Tabata et al., 2004), AADAC is specifically localized in the endoplasmic reticulum (Frick et al., 2004). Previously, we demonstrated that the AADAC protein level per total microsomal protein content is almost equal between HIM and HLM (Watanabe et al., 2009). This is consistent with the finding that the eslicarbazepine acetate hydrolase activities in HIM and HLM were close to each other (Fig. 2). The similarities of K_m values (Fig. 3) and the inhibition pattern (Fig. 4) between HIM, HLM, and recombinant AADAC, as well as similar inhibition patterns with other AADAC substrates, flutamide, indiplon and ketoconazole (Watanabe et al., 2009; Shimizu et al., 2014; Fukami et al., 2016), supported the predominant role of AADAC on eslicarbazepine acetate hydrolysis in the human intestines and liver. The correlation between eslicarbazepine acetate hydrolase activity and AADAC protein expression in human liver samples (Fig. 5) also strengthened the responsibility of AADAC

for eslicarbazepine acetate hydrolysis. Collectively, we clearly demonstrated that eslicarbazepine acetate is specifically hydrolyzed by AADAC.

For the compounds used in the inhibition study, it has been reported that the plasma concentration of vinblastine is 200 nM immediately after intravenous administration of the clinical dose (Nelson, 1982). Because the IC_{50} values of vinblastine for AADAC activities are on the order of μ M (Shimizu et al., 2014), drug-drug interactions between eslicarbazepine acetate and vinblastine are unlikely to be critical in clinical practice. EGCg is a major polyphenolic constituent in green tea, and its concentration in green tea is approximately 25 μ M (Dashwood et al., 2002). The plasma concentration of EGCg after taking 20 mg green tea solids/kg body weight, which corresponds to 195 mg EGCg in a person weighing 70 kg, was approximately 0.2 μ M (Lee et al., 2002), but the small intestine may be exposed to EGCg at concentrations sufficiently inhibiting AADAC depending on dietary habitat. Since it is known that the bioavailability of EGCg is low (Gan et al., 2018; Dai et al., 2020), *in vivo* study would be required to clarify whether EGCg intake affects the pharmacokinetics of AADAC substrates in humans.

It is known that the human AADAC gene is genetically polymorphic. Previously, we reported that a SNP of g.148008T>C (X400Q) in AADAC results in a considerable decrease in hydrolase activities for PNPA, flutamide, phenacetine, and rifampicin (Shimizu et al., 2012). In the present study, we found that the V172I variant showed higher activities than the wild type, whereas the R248S or X400Q variants showed lower activities than the wild type (Fig. 6). In the amino acid residues of AADAC, Ser189, Asp343, and His373 form the catalytic triad, which is essential for the catalytic activity (Williams et al., 2010). It is worth examining the possibility that Val172 and Arg248 might be three-dimensionally close to the substrate pocket containing the catalytic triad, leading to the alternation of the structure or size of the substrate pocket. Since the three-dimensional structure of AADAC has not yet been elucidated, progress in research is expected. In this study, the frequency of the AADAC gene deletion type in Caucasians was calculated to be 0.7%, but no carriers were found in the other populations. Originally, the deletion type was found in Europeans, and in a large European

cohort, a significant association was observed between *AADAC* gene deletion and Tourette syndrome, which is a common neurodevelopmental disorder characterized by movement tic and vocal tic ($P = 4.4 \times 10^{-4}$; odds ratio = 1.9, Bertelsen et al., 2016). Another study revealed that Chinese patients with Tourette syndrome possessed an *AADAC* allele with R248S and an allele with c.361+1G>A, which is predicted to produce mRNA transcripts lacking exon 2, heterozygously (Yuan et al., 2018). Therefore, the R248S variant has been suggested to cause dramatically decreased enzyme activity. Our study could directly prove that the R248S variant has drastically decreased activity. Because the global frequency of c.361+1G>A appears to be quite low (0.008%, Yuan et al., 2018), genotyping of its *AADAC* variant was not performed in this study. Elucidation of the role of *AADAC* in neurodevelopment is still awaited.

It has been reported that there was 25-fold interindividual difference in serum concentration of eslicarbazepine/dose ratio in 168 Norwegian patients taking eslicarbazepine acetate (Svendsen et al., 2017). In package insert, it was described that there was no significant difference in the area under the curve of eslicarbazepine between ethnics (Caucasians $n = 849$, Blacks $n = 53$, Asians $n = 65$, and Others $n = 51$). This is consistent with the results of our study, showing low frequencies of variants affecting enzyme activity. Factors other than *AADAC* genetic polymorphisms might be involved in the interindividual differences. Eslicarbazepine is further metabolized by UDP-glucuronosyltransferases (Perucca et al., 2011). The interindividual differences in serum level of eslicarbazepine may be accounted for by the differences in the catalytic potency of UDP-glucuronosyltransferase.

In conclusion, we found that eslicarbazepine acetate is specifically hydrolyzed by *AADAC* in human liver and intestines, and the genetic polymorphism of *AADAC* could be a factor affecting drug response, although the allele frequencies of variants appear to be low in all populations.

Authorship Contributions

Participated in research design: Hirosawa, Fukami, Tashiro, Nakano, Nakajima

Conducted experiments: Hirosawa, Tashiro, Kisui

Contributed new reagents or analytical tools: Hirosawa, Tashiro, Kisui

Performed data analysis: Hirosawa, Fukami, Tashiro

Wrote or contributed to the writing of manuscript: Hirosawa, Sakai, Nakajima

References

- Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, and Soares-da-Silva P (2008) Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. *Eur J Clin Pharmacol* **64**: 267-273.
- Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, and Soares-da-Silva P (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. *Epilepsy Res* **89**: 278-285.
- Bertelsen B, Stefánsson H, Riff Jensen L, Melchior L, Mol Debes N, Groth C, Skov L, Werge T, Karagiannidis I, Tarnok Z, Barta C, Nagy P, Farkas L, Brøndum-Nielsen K, Rizzo R, Gulisano M, Rujescu D, Kiemeny LA, Tosato S, Nawaz MS, Ingason A, Unnsteinsdottir U, Steinberg S, Ludvigsson P, Stefansson K, Kuss AW, Paschou P, Cath D, Hoekstra PJ, Müller-Vahl K, Stuhmann M, Silahatoglu A, Pfundt R, and Tümer Z (2016) Association of AADAC deletion and Gilles de la Tourette syndrome in a large european cohort. *Biol Psychiatry* **79**: 383-391.
- Cerny MA (2016) Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. *Drug Metab Dispos* **44**: 1246-1252.
- Dai W, Ruan C, Zhang Y, Wang J, Han J, Shao Z, Sun Y, and Liang J (2020) Bioavailability enhancement of EGCG by structural modification and nano-delivery: A review. *J Func Food* **65**: 103732.
- Dashwood WM, Orner GA, and Dashwood RH (2002) Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H₂O₂ at physiologically relevant EGCG concentrations. *Biochem Biophys Res Commun* **296**: 584-588.
- Galiana GL, Gauthier AC, and Mattson RH (2017) Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures. *Drugs R D* **17**: 329-339.

- Gan RY, Li HB, Sui ZQ, and Corke H. (2018) Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. *Crit Rev Food Sci Nutr* **58**: 924-941.
- Frick C, Atanasov AG, Arnold P, Ozols J, and Odermatt A (2004) Appropriate function of 11 β -hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. *J Biol Chem* **279**: 31131-31138.
- Fricke-Galindo I, Llerana A, Jung-Cook H, and López-López M (2018) Carbamazepine adverse drug reactions. *Exp Rev Clin Pharmacol* **11**: 705-718.
- Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, and Yokoi T (2010) In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. *Drug Metab Dispos* **38**: 2173-2178.
- Fukami T and Yokoi T (2012) The emerging role of human esterases. *Drug Metab Pharmacokinet* **27**: 466-477.
- Fukami T, Kariya M, Kurokawa T, Iida A, and Nakajima M (2015) Comparison of substrate specificity between human arylacetamide deacetylase and carboxylesterases. *Eur J Pharm Sci* **78**: 47-53.
- Fukami T, Iida A, Konishi K, and Nakajima M (2016) Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. *Biochem Pharmacol* **116**: 153-161.
- Heymann E and Krisch K (1967) Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases. *Hoppe Seylers Z Physiol Chem* **348**: 609-619.
- Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ, Potter PM, Redinbo MR, Robert J, Satoh T, Yamashita T, Yan B, Yokoi T, Zechner R, and Maltais LJ (2010) Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. *Mamm Genome* **21**: 427-441.

- Kobayashi Y, Fukami T, Nakajima A, Watanabe A, Nakajima M, and Yokoi T (2012) Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. *Drug Metab Dispos* **40**: 671-679.
- Koch MW and Polman SK (2009) Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. *Cochrane Database Syst Rev* (4), CD006453.
- Kurokawa T, Fukami T, Yoshida T, and Nakajima M (2016) Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog. *Drug Metab Dispos* **44**: 409-416.
- Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, and Yang CS (2002) Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. *Cancer Epidemiol Biomarkers Prev* **11**: 1025-1032.
- Maia J, Vaz-da-Silva M, Almeida L, Falcao A, Silveira P, Guimaraes S, Graziela P, and Soares-da-Silva P (2005) Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). *Drugs R D* **6**: 201-206.
- Malátková P, Havlíková L, and Wsól V (2014) The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. *Chem Biol Interact* **220**: 241-247.
- Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, and Yokoi T (2011) Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. *Biochem Pharmacol* **82**: 1747-1756.
- Nelson RL (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. *Med Pediatr Oncol* **10**: 115-127.
- Nunes T, Rocha JF, Falcão A, Almeida L, and Soares-da-Silva P (2013) Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. *Epilepsia* **54**: 108-116.

- Perucca E, Elger C, Halász P, Falcão A, Almeida L, Soares-da-Silva P (2011) Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. *Epilepsy Res* **96**: 132-139.
- Potschka H, Soerensen J, Pekcec A, Loureiro A, and Soares-da-Silva P (2014) Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. *Epilepsy Res* **108**: 212-222.
- Satoh T and Hosokawa M (2006) Structure, function and regulation of carboxylesterases. *Chem Biol Interact* **162**: 195-211.
- Shimizu M, Fukami T, Nakajima M, and Yokoi T (2014) Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. *Drug Metab. Dispos* **42**: 1103-1109.
- Shimizu M, Fukami T, Kobayashi Y, Takamiya M, Aoki Y, Nakajima M, and Yokoi T (2012) A novel polymorphic allele of human *arylacetamide deacetylase* leads to decreased enzyme activity. *Drug Metab Dispos* **40**: 1183-1190.
- Shimizu M, Fukami T, Ito Y, Kurokawa T, Kariya M, Nakajima M, and Yokoi T (2014) Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. *Drug Metab Dispos* **42**: 751-758.
- Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, and Johannessen Landmark C (2017) Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. *Epilepsy Res* **129**: 125-131.
- Tabata T, Katoh M, Tokudome S, Nakajima M, and Yokoi T (2004) Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver. *Drug Metab Dispos* **32**: 1103-1110.
- Watanabe A, Fukami T, Nakajima M, Takamiya M, Aoki Y, and Yokoi T (2009) Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. *Drug Metab Dispos* **37**: 1513-1520.

- Watanabe A, Fukami T, Takahashi S, Kobayashi Y, Nakagawa N, Nakajima M and Yokoi T (2010) Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. *Drug Metab Dispos* **38**: 1532-1537.
- Williams ET, Wang H, Wrighton SA, Qian YW, and Perkins EJ (2010) Genomic analysis of the carboxylesterases: identification and classification of novel forms. *Mol Phylogenet Evol* **57**: 23-34.
- Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. *Clin Cancer Res* **8**: 2605-2611.
- Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, Oda M, and Watanabe K (2006) Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. *Drug Metab Pharmacokinet* **21**: 147-155.
- Yuan L, Zheng W, Yang Z, Deng X, Song Z, and Deng H (2018) Association of the AADAC gene and Tourette syndrome in a Han Chinese cohort. *Neurosci Lett* **666**: 24-27.

Footnotes

This work was supported in part by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K07082).

The authors declare that there are no conflicts of interest.

Send reprint requests to: Tatsuki Fukami, Ph.D. Faculty of Pharmaceutical Sciences,
Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. E-mail:
tatsuki@p.kanazawa-u.ac.jp

Figure legends

Fig. 1. Metabolic pathways of carbamazepine, oxcarbazepine, and eslicarbazepine acetate in humans.

Fig. 2. Eslicarbazepine acetate hydrolase activities in HLM, HLC, HIM, HIC, and recombinant hydrolases. The substrate concentration was 1 mM. Each column represents the mean \pm SD of triplicate determinations. *** $P < 0.001$, compared with the activity of the control using ANOVA followed by Tukey's test.

Fig. 3. Kinetic analysis of eslicarbazepine acetate hydrolase activities in HIM, HLM, and recombinant AADAC. The kinetic parameters were estimated from the fitted curve using the KaleidaGraph computer program designed for nonlinear regression analysis. Each data point represents the mean \pm SD of triplicate determinations.

Fig. 4. Effects of chemical inhibitors on eslicarbazepine acetate hydrolase activities in HIM, HLM, and recombinant AADAC. The substrate concentration was 1 mM. The concentrations of the inhibitors were as follows: DFP, BNPP and PMSF, 100 μ M; telmisartan, 5 μ M; vinblastine and EGCg, 50 μ M; and CaCl₂, 1 mM. The control activities in HIM, HLM, and recombinant AADAC were 112.7 ± 7.6 , 149.5 ± 2.5 , 92.9 ± 4.0 nmol/min/mg protein, respectively. Each column represents the mean \pm SD of triplicate determinations.

Fig. 5. Correlation analysis between AADAC protein levels and eslicarbazepine acetate hydrolase activities in a panel of 25 human liver microsomes. The AADAC protein levels determined by immunoblot analysis are represented as relative levels to the sample with the lowest expression level. The eslicarbazepine acetate hydrolase activity at a substrate concentration of 1 mM was determined by HPLC.

Fig. 6. Effects of AADAC variants on the hydrolase activities of eslicarbazepine acetate and other AADAC substrates. (A) Eslicarbazepine acetate, (B) PNPA, (C) ketoconazole, (D) phenacetin, and (E) rifampicin hydrolase activities by recombinant human AADAC wild type and variants were measured by HPLC or LC-MS/MS. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$, compared with the activity of wild type using an unpaired, two-tailed Student's t -test. Each column represents the mean \pm SD of triplicate determinations. The eslicarbazepine acetate, PNPA, ketoconazole, phenacetin, and rifampicin hydrolase activities by wild type were 101.1 ± 3.4 nmol/min/mg protein, 726.6 ± 21.8 nmol/min/mg protein, 33.0 ± 2.3 pmol/min/mg protein, 4.6 ± 0.0 nmol/min/mg protein, and 63.9 ± 2.2 pmol/min/mg protein, respectively.

Table 1. Characteristics of 25 donors of liver samples used in this study.

No	Sex	Age (yr)	Ethnic	Cause of death
1	Male	36	Caucasian	Head trauma
2	Male	46	Caucasian	Anoxia
3	Female	35	Hispanic	Intracerebral hematoma
4	Male	68	Caucasian	Cerebrovascular accident
5	Male	63	Caucasian	Intracerebral hematoma
6	Female	59	Caucasian	Traffic accident
7	Male	49	Hispanic	Head trauma
8	Female	32	Hispanic	Subarachnoid hemorrhage
9	Female	33	Hispanic	Cerebrovascular accident
10	Male	38	Caucasian	Head trauma
11	Male	56	Caucasian	Intracerebral hematoma
12	Female	34	Black	Cerebrovascular accident
13	Female	35	Hispanic	Intracerebral hematoma
14	Male	36	Caucasian	Intracerebral hematoma
15	Male	57	Asian	Intracerebral hematoma
16	Male	33	Caucasian	Brain tumor
17	Male	60	Caucasian	Intracerebral hematoma
18	Male	52	Caucasian	Cerebrovascular accident
19	Male	62	Asian	Intracerebral hematoma
20	Female	52	Asian	Cerebrovascular accident
21	Male	60	Hispanic	Cerebrovascular accident
22	Female	47	Caucasian	S/P code
23	Male	54	Caucasian	Cerebrovascular accident
24	Female	51	Asian	Intracerebral hematoma
25	Male	43	Caucasian	Intracerebral hematoma

Table 2. SNPs investigated in this study.

SNP ID	SNP	Amino acid change	Allele frequency (%)
rs144650170	c.310A>G	T74A	4.3 (East Asians)
rs35084477	c.604G>A	V172I	3.9 (Africans)
rs186388618	c.834A>T	R248S	0.6 (East Asians)
rs1803155	c.931G>A	V281I	60.0 (All populations)
rs1733692	c.1188C>G	N366K	0.7 (Americans)
rs61733692	c.1288T>C	X400Q	0.1 (Americans)

All frequencies were referred to dbSNP.

Table 3. Primers used to introduce mutations in the *AADAC* gene and for *AADAC* genotyping.

Primers used to introduce mutations		
Mutation	Sequence (5'→3')	
T74A	Sense	CCCACCAG <u>C</u> CTCAGATGAAAATGTCACTGTGAT
	Antisense	TCTGAGGCTGGTGGGACTTCATCAAAGCTCCCG
V172I	Sense	TAAAAAAAT <u>T</u> CTTGCAAAATATGGTGTGAACCC
	Antisense	GCAAGA <u>A</u> TTTTTTTACGTAAGAACCACCTTAAG
R248S	Sense	GGTCAGT <u>T</u> TTCTGGAGTGAATATTTACCACTGA
	Antisense	CTCCAGAA <u>A</u> CTGACCATGAGTGATTTGGATAGA
N366K	Sense	TCATAAG <u>C</u> ATGTTGAGGATGGATTCCATGGAGC
	Antisense	TCAACATG <u>C</u> TTATGAGTCACCTGAACCCCAGTG
Primers used for <i>AADAC</i> genotyping		
Mutation	Sequence (5'→3')	
V172I	Sense	GGTCAGT <u>T</u> TTCTGGAGTGAATATTTACCACTGA
	Antisense	CTCCAGAA <u>A</u> CTGACCATGAGTGATTTGGATAGA
R248S	Sense	CCCACCAGCCTCAGATGAAAATGTCACTGTGAT
	Antisense	TCTGAGGCTGGTGGGACTTCATCAAAGCTCCCG
Deletion type	Wild	Sense CTGGGATGCGGGCAATGTTA
		Antisense CTATGACAGAAGCAGGGATTG
	Deletion	Sense GGTACAGCAAGAAGCTCTGATG
		Antisense GGTGAATGTCTTCAAGGTTGGAG

The underlined letters indicate mutations.

Table 4. Kinetic parameters of eslicarbazepine acetate hydrolase activities.

	<i>K_m</i>	<i>V_{max}</i>	<i>CL_{int}</i>
	(mM)	(nmol/min/mg protein)	(mL/min/mg protein)
HIM	1.16 ± 0.20*	202.3 ± 7.2	0.17 ± 0.02
HLM	0.72 ± 0.08	283.7 ± 4.1	0.40 ± 0.05
Recombinant AADAC	0.79 ± 0.11	157.5 ± 3.9	0.20 ± 0.02

**P* < 0.05, compared with the *K_m* value by recombinant AADAC using ANOVA followed by Tukey's test.

Table 5. Allele frequencies of *AADAC* variants altering enzymatic activities in four populations.

Population	No. of subjects	Allelic Frequencies (%)			Gene deletion type
		g.14008T>C (X400Q) [†]	g.10583G>A (V172I)	g.13452A>T (R248S)	
Japanese	176	0	0	0	0
Koreans	205	0	0	0	0
Caucasians	209	1.3	0	0	0.7
African Americans	218	2.0	0.5	0	0

[†] Shimizu et al. (2012)

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6



Supplemental Materials to journal of “Drug Metabolism and Disposition”

Manuscript number: DMD-AR-2020-000295


Role of human AADAC on hydrolysis of eslicarbazepine acetate and effects of *AADAC* genetic polymorphisms on hydrolase activity

Keiya Hirose, Tatsuki Fukami, Kiyomichi Tashiro, Yoshiyuki Sakai, Fumiya
Kisui, Masataka Nakano, Miki Nakajima


Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences,
Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan (K. H., T. F.,
K. T., Y. S., Ma.N., Mi. N.); WPI Nano Life Science Institute, Kakuma-machi,
Kanazawa 920-1192, Japan (T. F., Ma. N., Mi. N.)

Supplementary Fig. 1S

Wild type



Deletion



Supplementary Fig. 1S. Schematic diagram of the locations where the primer pairs for genotyping of *AADAC* wild type and gene deletion type were designed. PCR amplification was performed with the primer pairs indicated by horizontal arrows.